Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor

[tetano]

Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print] Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Keam B^1,2, Kang CK¹, Jun KI¹, Moon SM³, Suh KJ³, Lee DW^1,2, Ock CY^1,2, Kim M^1,2, Choi Y⁴, Lim Y^1,2, Lee KH^1,2, Kim SH³, Kim TM^1,2, Kim TY^1,2, Oh DY^1,2, Kim DW^1,2, Im SA^1,2, Lee JS³, Kim ES³, Kim HB³, Kim NJ¹, Kim YJ³, Park WB¹, Oh MD¹.
Author information

1 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. 4 Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.

Abstract

Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs, n=46) or cytotoxic agents (n=90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results supports administration of annual influenza vaccinations for patients with cancer that receive ICIs.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.


KEYWORDS:

Influenza; immune checkpoint inhibitor; immune-related adverse event; immunogenicity; vaccination

PMID: 31680143 DOI: 10.1093/cid/ciz1092